PLOD1 and testicular cancer: Although largely the selected measurement in the Chemocog cohort fell close to 6 months in line with standard surveillance and the iTestis cohort, reliability in diagnosing hypogonadism and establishing a temporal trend between testicular cancer treatment and hypogonadism would benefit from analysing multiple assessments rather than relying on a single testosterone and LH level measurement.